Expert Interview
Discussing commercial uptake of Winrevair (sotatercept) in treating pulmonary arterial hypertension (PAH)
Ticker(s): MRKInstitution: UPENN
- Chief, Pulmonary, Allergy and Critical Care, Penn Presbyterian Medical Center, Director, Pulmonary Vascular Disease Program and Professor of Medicine at the Hospital of the University of Pennsylvania.
- Treats ~200 patients with PAH.
- Research focuses on the diagnosis and treatment of pulmonary vascular disease and pulmonary thromboembolic disease.
How many PAH patients do you treat?
Added By: wilson_adminHow has your experience with Winrevair been?
Added By: wilson_adminDo you anticipate your prescribing patterns to increase, stay the same, or decrease?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
